National Center for Advancing Translational Sciences; Notice of Closed Meeting, 11047-11048 [2017-03165]
Download as PDF
Federal Register / Vol. 82, No. 32 / Friday, February 17, 2017 / Notices
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
designated contact person at least
fourteen (14) business days prior to the
meeting. Members of the public will
have an opportunity to provide
comments at the meeting. Public
comments will be limited to three
minutes per speaker. Individuals who
would like to submit written statements
should mail or fax their comments to
the Office of Minority Health at least
seven (7) business days prior to the
meeting. Any members of the public
who wish to have printed material
distributed to ACMH committee
members should submit their materials
to the Designated Federal Officer,
ACMH, Tower Building, 1101 Wootton
Parkway, Suite 600, Rockville,
Maryland 20852, prior to close of
business on Thursday, March 16, 2017.
Dated: February 14, 2017.
Minh Wendt,
Designated Federal Officer, ACMH, Office of
Minority Health, U.S. Department of Health
and Human Services.
[FR Doc. 2017–03247 Filed 2–16–17; 8:45 am]
BILLING CODE 4150–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on HIV/AIDS
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Presidential Advisory Council on HIV/
AIDS (PACHA or the Council) will be
holding a meeting to continue
discussions and possibly develop
recommendations regarding People
Living with HIV/AIDS. The meeting will
be open to the public.
DATES: The Council meeting is
scheduled to be held on March 13, 2017,
from 9:00 a.m. to approximately 5:00
p.m. (ET) and March 14, 2017, from 9:00
a.m. to approximately 12:00 p.m. (ET).
The meeting will be open to the public.
ADDRESSES: 330 Independence Avenue
SW., Washington, DC 20201 in the
Snow Room (Conference Room 5051).
FOR FURTHER INFORMATION CONTACT: Ms.
Caroline Talev, Public Health Analyst,
Presidential Advisory Council on HIV/
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:38 Feb 16, 2017
Jkt 241001
AIDS, 330 C Street SW., Room L106B,
Washington, DC 20024; (202) 795–7622
or Caroline.Talev@hhs.gov. More
detailed information about PACHA can
be obtained by accessing the Council’s
page on the AIDS.gov Web site at
www.aids.gov/pacha.
SUPPLEMENTARY INFORMATION: PACHA
was established by Executive Order
12963, dated June 14, 1995, as amended
by Executive Order 13009, dated June
14, 1996. In a memorandum, dated July
13, 2010, and under Executive Order
13703, dated July 30, 2015, the
President gave certain authorities to the
PACHA for implementation of the
National HIV/AIDS Strategy for the
United States (Strategy). PACHA is
currently operating under the authority
given in Executive Order 13708, dated
September 30, 2015.
PACHA provides advice, information,
and recommendations to the Secretary
regarding programs, policies, and
research to promote effective treatment,
prevention, and cure of HIV disease and
AIDS, including considering common
co-morbidities of those infected with
HIV as needed, to promote effective HIV
prevention and treatment and quality
services to persons living with HIV
disease and AIDS.
Substantial progress has been made in
addressing the domestic HIV epidemic
since the Strategy was released in July
2010. Under Executive Order 13703, the
National HIV/AIDS Strategy for the
United States: Updated to 2020
(Updated Strategy) was released.
PACHA shall contribute to the federal
effort to improve HIV prevention and
care.
The functions of the Council are
solely advisory in nature.
The Council consists of not more than
25 members. Council members are
selected from prominent community
leaders with particular expertise in, or
knowledge of, matters concerning HIV
and AIDS, public health, global health,
philanthropy, marketing or business, as
well as other national leaders held in
high esteem from other sectors of
society. Council members are appointed
by the Secretary or designee, in
consultation with the White House
Office on National AIDS Policy. The
agenda for the upcoming meeting will
be posted on the AIDS.gov Web site at
www.aids.gov/pacha.
Public attendance at the meeting is
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify Caroline
Talev at Caroline.Talev@hhs.gov. Due to
space constraints, pre-registration for
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
11047
public attendance is advisable and can
be accomplished by contacting Caroline
Talev at Caroline.Talev@hhs.gov by
close of business on Monday, March 6,
2017. Members of the public will have
the opportunity to provide comments
during the meeting. Comments will be
limited to two minutes per speaker. Any
individual who wishes to participate in
the public comment session must
register with Caroline Talev at
Caroline.Talev@hhs.gov by close of
business on Monday, March 6, 2017;
registration for public comment will not
be accepted by telephone. Individuals
are encouraged to provide a written
statement of any public comment(s) for
accurate minute taking purposes. Public
comment will be limited to two minutes
per speaker. Any members of the public
who wish to have printed material
distributed to PACHA members at the
meeting are asked to submit, at a
minimum, 1 copy of the material(s) to
Caroline Talev, no later than close of
business on Monday, March 6, 2017.
Dated: February 9, 2017.
B. Kaye Hayes,
Executive Director, Presidential Advisory
Council on HIV/AIDS.
[FR Doc. 2017–03245 Filed 2–16–17; 8:45 am]
BILLING CODE 4150–43–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel Review of RFA–TR–16–021:
Coordination Center for the CTSA Program
(U24).
Date: March 14, 2017.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\17FEN1.SGM
17FEN1
11048
Federal Register / Vol. 82, No. 32 / Friday, February 17, 2017 / Notices
Place: National Institutes of Health, 6701
Democracy Blvd., Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, Office of Scientific
Director, National Center for Advancing
Translational Sciences (NCATS), National
Institutes of Health, 6701 Democracy Blvd.,
Democracy 1, Room 1080, Bethesda, MD
20892–4878, 301–451–2405, henriquv@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B–Cooperative Agreements;
93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: February 13, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03165 Filed 2–16–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
mstockstill on DSK3G9T082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Kidney
Precision Medicine Program Applications
Review Meeting.
Date: March 14–15, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Alexandria Old
Town/Duke Street, 1456 Duke Street,
Alexandria, VA 22314.
Contact Person: Jason D. Hoffert, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7343, 6707 Democracy Boulevard,
Bethesda, MD 20817, 301–496–9010,
hoffertj@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
VerDate Sep<11>2014
17:38 Feb 16, 2017
Jkt 241001
Special Emphasis Panel; Pathogenesis of
Calcium Nephrolithiasis (P01).
Date: March 15, 2017.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Pediatric
Nephrology Centers.
Date: March 15–16, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Capital View, 2850
South Potomac Avenue, Arlington, VA
22202.
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Indomethacin and
the Microbiome: The Stent vs Indomethacin
Trial.
Date: March 16, 2017.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Exploratory Studies
for Delineating Microbiome: Host
Interactions in Obesity, Digestive and Liver
Diseases and Nutrition (R21).
Date: March 21, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Alexandria Old
Town, 1456 Duke Street, Alexandria, VA
22314.
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Nutrition Obesity
Research Centers (P30).
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Date: March 22, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Thomas A. Tatham, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7021, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 13, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03167 Filed 2–16–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; SBIR/STTR
Applications in Drug Discovery and
Development.
Date: March 13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, 301–435–1180, ruvinser@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Endocrinology, Metabolism,
Nutrition and Reproductive Sciences.
E:\FR\FM\17FEN1.SGM
17FEN1
Agencies
[Federal Register Volume 82, Number 32 (Friday, February 17, 2017)]
[Notices]
[Pages 11047-11048]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03165]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel Review of RFA-TR-16-021:
Coordination Center for the CTSA Program (U24).
Date: March 14, 2017.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 11048]]
Place: National Institutes of Health, 6701 Democracy Blvd.,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Victor Henriquez, Ph.D., Scientific Review
Officer, Office of Scientific Director, National Center for
Advancing Translational Sciences (NCATS), National Institutes of
Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD
20892-4878, 301-451-2405, henriquv@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B-Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: February 13, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03165 Filed 2-16-17; 8:45 am]
BILLING CODE 4140-01-P